Companies
bioMérieux
leading the world in clinical microbiology and rapid syndromic testing for infectious diseases.
- Country
- France
- Ticker
- BIM.PA
microbiology
eu
legacy
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| analytics-pat | ✓ | ✓ | — | ✓ |
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Acquired BioFire Diagnostics for $450 million in 2013, funded through indebtedness including new lines of credit | biospace.com |
| Capacity | Maintains 19 bio-industrial sites globally, with ongoing investment in capacity expansion, automation, and internalization of production in France and the US | biomerieux.com |
| Certification | Certified over 250 Class B, C, and D products and 200 Class A devices under IVDR regulation as of 2024; maintains ISO-compliant quality management systems | biomerieux.com |
| Regulatory approval | Numerous FDA clearances and CE markings for diagnostic platforms (e.g., BIOFIRE, SPOTFIRE, VITEK) | biomerieux.com · biospace.com · marketsandmarkets.com |
| Production site | 19 bio-industrial sites, including facilities in Marcy-l’Étoile and La Balme-les-Grottes, France, and Salt Lake City, USA | biomerieux.com |
| Headcount | Approximately 15,000 employees as of 2025/2026 | biomerieux.com |
| Revenue | €4.1 billion in 2025 | biomerieux.com |
Independent sources: biospace.com · marketsandmarkets.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Diagnostics & biosensors | diagnostics-medtech | Low | → |
| Point-of-care molecular diagnostics | diagnostics-medtech | Low | → |
| Sterility testing systems | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.